Výsledky vyhledávání - "Cnm Breviglieri"

Akademický článek

REVOLUTIONIZING POST-TRANSPLANT CARE IN PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) WITH TAILORED MAINTENANCE THERAPIES: A LEAP TOWARDS ENHANCED SURVIVAL AGAINST ACTIVE DISEASE

Autor: CNM Breviglieri, RG Vasconcelos, CN Santos, VC Ginani, MRS Oliveira, ABW Batalha, JF Marques, GS Alencar, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S688- (2024)

Pediatric Acute Myeloid Leukemia (AML) presents significant treatment challenges, particularly post-transplant relapses. The use of the only specific immunotherapy for AML may increase transplant-related toxicities due to the calicheamicin. This scar

Externí odkaz: https://doaj.org/article/e55c74ee82c8490bb7e7420f999c4f65

Zobrazit plný text záznamu

Akademický článek

BLINATUMOMAB + DONOR LEUKOCYTE INFUSIONS (DLI) CAN BE USED TO PREVENT THE RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT)

Autor: CNM Breviglieri, VC Ginani, RG Vasconcelos, CN Santos, ABW Batalha, MRS Oliveira, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S686- (2024)

Chimeric antigen receptor (CAR) T-cell therapy is a choice for ALL relapsed post-HCT but is hindered by cost and the required lengthy washout period, emphasizing the need for new strategies to prevent relapse. For those at high relapse risk due to di

Externí odkaz: https://doaj.org/article/74d8ff45a74541df89beedfbca6a21b1

Zobrazit plný text záznamu

Akademický článek

BRIDGING THE GAP IN POST-TRANSPLANT CARE FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INNOVATIVE MAINTENANCE STRATEGIES TO REDUCE RELAPSE RATE AND ENHANCE SURVIVAL

Autor: CNM Breviglieri, CN Santos, RG Vasconcelos, VC Ginani, ABW Batalha, MRS Oliveira, GS Alencar, JF Marques, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S688-S689 (2024)

Relapsed Acute Lymphoblastic Leukemia (ALL) post-hematopoietic stem cell transplantation (HCT) have very poor outcomes. Patients face increased toxicity and poorer responses to therapy. With limited access to Chimeric Antigen Receptor (CAR) T-cell th

Externí odkaz: https://doaj.org/article/dde0e2390c9542799a4ba743309d9af4

Zobrazit plný text záznamu

Akademický článek

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): A FEASIBLE CURATIVE OPTION WITH HLA-IDENTICAL OR HAPLOIDENTICAL DONORS

Autor: RV Gouveia, VC Ginani, CNM Breviglieri, G Zamperlini, VADN Varjão, J Marques, CMMSS Parrode, ABW Batalha, EH Goto, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S1010- (2024)

Introduction: HCT is the only curative option available in Brazil to SCD. Most patients do not have an unaffected Matched Sibling Donor (MSD), so alternative donor options are urgently needed. The Vanderbilt Global Haploidentical Learning Collaborati

Externí odkaz: https://doaj.org/article/14f74ec2663d4035996b2b0738b80ed2

Zobrazit plný text záznamu

Akademický článek

WHY DO PATIENTS WITH SICKLE CELL ANEMIA REFERRED TO HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) AND WILLING TO UNDERGO TRANSPLANT MAY NEVER HAVE IT? CAN WE CHANGE THIS REALITY?

Autor: RV Gouveia, LL Quintino, CM Lustosa, ASS Ibanez, MGAD Matos, CMMSS Parrode, VADN Varjão, CNM Breviglieri, VC Ginani, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S1038-S1039 (2024)

Introduction: HCT is the only curative option for patients with sickle cell anemia in our country. Unfortunately, few have an unaffected HLA-identical sibling donor. Haploidentical donors are a feasible and effective option. Objective: This study is

Externí odkaz: https://doaj.org/article/efc3a565875542008c183eec867cf75f

Zobrazit plný text záznamu

Akademický článek

A SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT2) MAY CURE MORE THAN 40% PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Autor: MF Cardoso, G Zamperlini, CNM Breviglieri, R Gouveia, VC Ginani, JF Marques, LL Quintino, LDS Domingues, MGAD Matos, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S533- (2023)

Introduction: Relapse of a malignant hematological disease after allogeneic HCT is associated with poor survival and may not be treated with a curative intent. However, a second HCT (HCT2) may achieve durable remission. Objective: To determine the ou

Externí odkaz: https://doaj.org/article/a4253c1a61cd4bc58f2d4f310857532d

Zobrazit plný text záznamu

Akademický článek

EXPERIÊNCIA DO RUXOLITINIB NO TRATAMENTO DE DOENÇA DO ENXERTO CONTRA O HOSPEDEIRO CRÔNICA EM CRIANÇAS SUBMETIDAS A TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOIÉTICAS (TCTH)

Autor: RV Gouveia, VC Ginani, G Zamperlini, CMCZ Oliveira, CNM Breviglieri, MGAD Matos, LDS Domingues, MV Pupim, JF Marques, PM Paiva, PA Soriano, FVB Santos, CF Andrade, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S260-S261 (2021)

Introdução: A DECH crônica é uma das maiores causas de morbimortalidade tardia relacionada ao TCTH. Uso prolongado de corticoide sistêmico provoca inúmeros efeitos deletérios, principalmente em crianças. Não existe um tratamento de segunda l

Externí odkaz: https://doaj.org/article/544b5472cb5d49f89e83390101061ac6

Zobrazit plný text záznamu

Akademický článek

EXPERIÊNCIA COM REGIMES DE CONDICIONAMENTO SUGERIDOS PELO GRUPO DE ESTUDOS DE LEUCEMIA MIELÓIDE AGUDA INFANTIL (GELMAI)

Autor: CNM Breviglieri, RV Gouveia, VC Ginani, CMCZ Oliveira, LDS Domingues, MGM Alves, G Zamperlini, PAM Soriano, JF Marques, A Seber

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S259-S260 (2021)

Introdução: A sobrevida das crianças com LMA submetidas a TCTH no Brasil entre 2008 e 2012 foi de 47%. O GELMAI está iniciando protocolo prospectivo com indução com baixas doses de quimioterapia para reduzir a mortalidade precoce. TCTH será in

Externí odkaz: https://doaj.org/article/dd6b78ec0854437bac174c655faa1bcc

Zobrazit plný text záznamu